Shulou(Shulou.com)12/24 Report--

CTOnews.com December 9 news, medical experts recently successfully developed a biological therapy, focusing on severe asthma patients, without the need for high doses of inhaled steroids, effectively relieve patients 'discomfort.

The results were published in The Lancet.

High doses of inhaled steroids have significant side effects, and the results of the multinational SHAMAL study show that 92% of patients with severe asthma can reduce the dose of inhaled steroids after using benralizumab biological therapy, and more than 60% of patients can stop all use.

The results of this study could have transformative implications for patients with severe asthma, minimizing or eliminating serious side effects of inhaled steroids, including an increased risk of osteoporosis, fractures, diabetes and cataracts.

Asthma is one of the most common respiratory diseases worldwide, affecting nearly 300 million people, of whom about 3 to 5 per cent suffer from severe asthma.

These people with severe asthma may experience daily symptoms of breathing difficulties, chest tightness and coughing, as well as recurrent asthma attacks that require frequent hospitalization.

Benarizumab is a biological therapy that reduces the number of inflammatory cells called eosinophils. This is produced in abnormal amounts in the airways of severe asthma patients and is closely associated with the development of asthma attacks.

The study followed 208 patients with severe asthma, tapering off high-dose inhaled steroids at varying doses for the first 32 weeks, followed by a 16-week maintenance period. In the 48-week study, approximately 90 percent of patients did not experience worsening asthma symptoms.

CTOnews.com Attaches Reference Address: https://doi.org/10.1016/S0140-6736(23)02284-5

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.